骨肉瘤是儿童最常见的骨原发恶性肿瘤,好发于儿童的生长高峰期,年发生率约为百万分之六〔1〕。随着新辅助化疗的应用和改进,骨肉瘤患者生存率已由单纯截肢的11%提高到60%~92%〔2、3〕。而影像学技术、手术技术、新辅助化疗以及生物医学工程学的进展更使约85%的患者可以接受保肢 Osteosarcoma is the most common primary malignancy of bone in children and occurs in the peak of the child’s growth at an annual rate of about 6 parts per million [1]. With the application and improvement of neoadjuvant chemotherapy, the survival rate of patients with osteosarcoma has increased from 11% of simple amputation to 60% to 92% (2,3). Advances in imaging techniques, surgical techniques, neoadjuvant chemotherapy, and biomedical engineering further make limb salvage possible in approximately 85% of patients